Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)

被引：37

作者：

Curigliano, Giuseppe ^{[1
,2
]}

Hu, Xichun ^{[3
]}

Dent, Rebecca Alexandra ^{[4
]}

Yonemori, Kan ^{[5
]}

Barrios Sr, Carlos H. ^{[6
]}

O'Shaughnessy, Joyce ^{[7
]}

Wildiers, Hans ^{[8
]}

Zhang, Qingyuan ^{[9
]}

Im, Seock-Ah ^{[10
]}

Saura, Cristina ^{[11
]}

Biganzoli, Laura ^{[12
]}

Sohn, Joohyuk ^{[13
]}

Levy, Christelle ^{[14
]}

Jacot, William ^{[15
]}

Begbie, Natasha ^{[16
]}

Ke, Jun ^{[17
]}

Patel, Gargi Surendra ^{[18
]}

Bardia, Aditya

机构：

[1] Univ Milan, Milan, Italy

[2] IRCCS, European Inst Oncol, Milan, Italy

[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[4] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[5] Natl Canc Ctr, Tokyo, Japan

[6] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil

[7] Baylor Univ, US Oncol Network, Texas Oncol, Med Ctr, Dallas, TX USA

[8] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium

[9] Harbin Med Univ Canc Hosp, Harbin, Peoples R China

[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[11] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[12] Santo Stefano Hosp, Azienda USL Toscana Ctr, Dept Oncol, Prato, Italy

[13] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea

[14] Ctr Francois Baclesse, Caen, France

[15] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, Montpellier, France

[16] AstraZeneca, Clin Dev, Late Stage Dev, Oncol R&D, Cambridge, England

[17] AstraZeneca, Biometr Oncol, Late Stage Dev, Oncol R&D, Waltham, MA USA

[18] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.17_suppl.LBA1000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA1000

引用

页码：LBA1000 / LBA1000

页数：1

共 50 条

[31] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
Omori, Y.
Enatsu, S.
Cai, Z.
Ishiguro, H.
CANCER RESEARCH, 2019, 79 (04)
[32] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma.
Shitara, Kohei
Enzinger, Peter C.
Mohapatra, Avani
Janjigian, Yelena Y.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS508 - TPS508
[33] Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany
Campone, M.
Frenel, J-S.
Kiver, V. I. I.
Woeckel, A.
Kerscher, A. G.
Krebs, M.
Leal, C. S.
Saglimbene, V. M.
Trankov, N.
Sadetsky, N.
Sjekloca, N.
Libert, O.
Kaushik, A. G.
Bocquet, F.
ANNALS OF ONCOLOGY, 2024, 35 : S375 - S376
[34] "Real world" characteristics, treatment patterns and outcomes of patients with hormone receptor positive (HR plus ), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC)
Twelves, C.
Cheeseman, S.
Thompson, M.
Riaz, M.
Perren, T.
Ahat-Donker, N.
Sopwith, W.
Myland, M.
Lee, A.
Turner, S.
Hall, G.
CANCER RESEARCH, 2019, 79 (04)
[35] MONARCH 2: Abemaciclib in Combination with Fulvestrant in Patients (pts) with Refractory Hormone Receptor Positive (HR plus )/Human Epidermal Growth Factor Receptor 2 Negative HER2-Advanced Breast Cancer (ABC) who Progressed on Endocrine Therapy (ET)
Sledge, G. W.
Toi, M.
Neven, P.
Sohn, J. H.
Inoue, K.
Pivot, X.
Burdaeva, O.
Okera, M.
Masuda, N.
Kaufman, P. A.
Koh, H.
Grischke, E. M.
Frenzel, M.
Lin, Y.
Barriga, S.
Smith, I. C.
Bourayou, N.
Llombart-Cussac, A.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 4 - 4
[36] Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)
Signorovitch, James
Wang, Jenny
Tan, Ruo-Ding
Thomason, Darren
Kageleiry, Andrew
Swallow, Elyse
CANCER RESEARCH, 2015, 75
[37] ALTERNATIVE: safety and efficacy of lapatinib (L), trastuzumab (T), or both in combination with an aromatase inhibitor (Al) for the treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer
Johnston, S.
Wroblewski, S.
Huang, Y.
Harvey, C.
Nagi, F.
Franklin, N.
Gradishar, W.
CANCER RESEARCH, 2012, 72
[38] Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
Johnston, Stephen R. D.
Hegg, Roberto
Im, Seock-Ah
Park, In Hae
Burdaeva, Olga
Kurteva, Galina
Press, Michael F.
Tjulandin, Sergei
Iwata, Hiroji
Simon, Sergio D.
Kenny, Sarah
Sarp, Severine
Izquierdo, Miguel A.
Williams, Lisa S.
Gradishar, William J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (01) : 79 - +
[39] Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
Hayashi, Naoki
Niikura, Naoki
Yamauchi, Hideko
Nakamura, Seigo
Ueno, Naoto T.
BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 523 - 531
[40] Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
Naoki Hayashi
Naoki Niikura
Hideko Yamauchi
Seigo Nakamura
Naoto T. Ueno
Breast Cancer Research and Treatment, 2013, 137 : 523 - 531

← 1 2 3 4 5 →